Aurobindo Pharma has secured consent from the Drugs Controller General of India (DCGI) for manufacturing and distributing its generic version of Covid drug Molnupiravir under the brand name — Molnaflu. The Indian pharma company had previously acquired the licensing rights for the generic version of MSD and Ridgeback Biotherapeutics’ Molnupiravir. A non-exclusive voluntary licensing agreement […]
Five Indian pharma companies – Cipla, Dr. Reddy’s Laboratories, Emcure Pharmaceuticals, Sun Pharmaceutical Industries, and Torrent Pharmaceuticals will join forces to undertake a clinical trial of Molnupiravir, an investigational oral anti-viral drug for the treatment of mild Covid-19 in India. The clinical trial of Molnupiravir will be in an outpatient setting. Molnupiravir is being developed […]
Cipla has entered into a non-exclusive licensing agreement with MSD (called Merck in the US and Canada) for the manufacturing and distribution of Molnupiravir (EIDD-2801/MK-4482), an investigational oral antiviral drug for the treatment of Covid-19 in patients who are not hospitalized. Molnupiravir is currently being assessed in a phase 3 trial. It is being developed […]